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Abstract
Objective To examine the efficacy and safety of the therapeutic regimen using oral and intravenous l-arginine for pediatric 
and adult patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS).
Methods In the presence and absence of an ictus of stroke-like episodes within 6 h prior to efficacy assessment, we corre-
spondingly conducted the systematic administration of oral and intravenous l-arginine to 15 and 10 patients with MELAS in 
two, 2-year, prospective, multicenter clinical trials at 10 medical institutions in Japan. Subsequently, patients were followed 
up for 7 years. The primary endpoint in the clinical trial of oral l-arginine was the MELAS scale, while that for intravenous 
l-arginine was the improvement rates of headache and nausea/vomiting at 2 h after completion of the initial intravenous 
administration. The relationships between the ictuses of stroke-like episodes and plasma arginine concentrations were 
examined.
Results Oral l-arginine extended the interictal phase (p = 0.0625) and decreased the incidence and severity of ictuses. Intra-
venous l-arginine improved the rates of four major symptoms—headache, nausea/vomiting, impaired consciousness, and 
visual disturbance. The maximal plasma arginine concentration was 167 μmol/L when an ictus developed. Neither death nor 
bedriddenness occurred during the 2-year clinical trials, and the latter did not develop during the 7-year follow-up despite 
the progressively neurodegenerative and eventually life-threatening nature of MELAS. No treatment-related adverse events 
occurred, and the formulations of l-arginine were well tolerated.
Conclusions The systematic administration of oral and intravenous l-arginine may be therapeutically beneficial and clini-
cally useful for patients with MELAS.
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